Silexion Submits Pivotal Phase 2/3 CTA for Pancreatic Cancer Drug to Germany, Expanding EU Trial
SLXN is trading near its 52-week low of $0.7 (8.7% above the low).
Summary
Silexion Therapeutics has successfully submitted its Phase 2/3 Clinical Trial Application (CTA) to Germany's BfArM for SIL204, its lead siRNA product candidate targeting KRAS-driven locally advanced pancreatic cancer. This submission is a critical regulatory milestone, positioning Germany as the Reporting Member State for the EU program and expanding the company's clinical development into a major European market. This follows prior positive Scientific Advice from BfArM and recent approval from the Israeli Ministry of Health for the same trial. For a micro-cap biotech company with a recent 'going concern' warning, this progress in its lead clinical program is highly material, de-risking the asset and potentially aiding future financing efforts. Traders will now monitor for BfArM approval and the planned Q2 2026 initiation of the Phase 2/3 trial.
At the time of this announcement, SLXN was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3M. The 52-week trading range was $0.70 to $22.36. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.